Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry Liebman who wrote (1914)	9/30/1997 4:22:00 AM
From: Henry Niman	of 6136

Larry, Here's what Reuter's said about the MS downgrade: LOS ANGELES, Sept 29 (Reuter) - Montgomery Securities analyst David Crosson Monday downgraded Agouron Pharmaceuticals Inc to a hold from a buy, citing new research suggesting the benefits of its Viracept AIDS drug may be limited. Viracept belongs to a class of AIDS drug known as protease inhibitors, which have in the past year become a cornerstone of the most aggressive AIDS therapies. But Crosson, who spoke from a research meeting in Toronto, cited new studies suggesting there may be a high failure rate of protease inhibitors in patients who were in an advanced stage of the disease. Crosson also cited a new study by Agouron showing patients who take Viracept frequently develop a cross-resistance to other protease inhibitors. These findings appeared to contradict earlier studies showing Viracept was less likely than other protease inhibitors to be associated with cross resistance. The drug's cross-resistance profile is key since patients usually develop a resistance to AIDS drugs after prolonged use and then need to switch to another brand. 14:24 09-29-97

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next